[go: up one dir, main page]

TN2013000405A1 - Ophthalmic treatments - Google Patents

Ophthalmic treatments

Info

Publication number
TN2013000405A1
TN2013000405A1 TNP2013000405A TN2013000405A TN2013000405A1 TN 2013000405 A1 TN2013000405 A1 TN 2013000405A1 TN P2013000405 A TNP2013000405 A TN P2013000405A TN 2013000405 A TN2013000405 A TN 2013000405A TN 2013000405 A1 TN2013000405 A1 TN 2013000405A1
Authority
TN
Tunisia
Prior art keywords
eye
compositions
pharmaceuticals
tramadol
analgesic
Prior art date
Application number
TNP2013000405A
Other languages
French (fr)
Inventor
Anant Sharma
Original Assignee
Optosolve Llp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2012/000330 external-priority patent/WO2012136969A2/en
Application filed by Optosolve Llp filed Critical Optosolve Llp
Publication of TN2013000405A1 publication Critical patent/TN2013000405A1/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Aqueous compositions suitable for topical administration to the human or animal eye contain at least one water-soluble polymeric ophthalmic lubricant, such as hyaluronate, carbomer gel or hypromellose, together with a water-soluble analgesic. The analgesic may be an opiod, particularly an opioid having an affinity for 5-HT receptors, such as tramadol. Typical tramadol levels would be in the range of 0.5% to 1.0% w/v. The aqueous compositions may for example be used as artificial tears, and as general ophthalmic lubricants for treating conditions such as dry eye or blepharitis. Further compositions combine ophthalmologically- active agents, such as pharmaceuticals, with opioids, such as tramadol in particular. These compositions may be used to treat the eye while reducing pain or discomfort that would normally be produced by administering these particular pharmaceuticals to the eye, and increasing the efficacy of the pharmaceuticals. Compositions are also disclosed, containing opioids with 5-HT receptor activity, which are of general use in alleviating pain in and around the eye.
TNP2013000405A 2011-04-05 2013-10-04 Ophthalmic treatments TN2013000405A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1105732.0A GB201105732D0 (en) 2011-04-05 2011-04-05 Ophthalmic lubricants
PCT/GB2012/000330 WO2012136969A2 (en) 2011-04-05 2012-04-05 Ophthalmic treatments

Publications (1)

Publication Number Publication Date
TN2013000405A1 true TN2013000405A1 (en) 2015-03-30

Family

ID=44071967

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000405A TN2013000405A1 (en) 2011-04-05 2013-10-04 Ophthalmic treatments

Country Status (2)

Country Link
GB (1) GB201105732D0 (en)
TN (1) TN2013000405A1 (en)

Also Published As

Publication number Publication date
GB201105732D0 (en) 2011-05-18

Similar Documents

Publication Publication Date Title
MX2013011314A (en) Ophthalmic treatments.
MX2020005217A (en) Ophthalmic composition and delivery device thereof.
MX2020010907A (en) Enhancement of delivery of lipophilic active agents across the blood-brain barrier and methods for treating central nervous system disorders.
MX2010002392A (en) Improved brimonidine compositions for treating erythema.
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
BR112015001158A2 (en) ophthalmic formulation and its use and method for improving, reducing or treating presbyopia
MX2010003774A (en) Aqueous ophthalmic formulations.
WO2011053801A3 (en) Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye
BR112012021905A2 (en) treatment of lupus nephritis using laquinimod
WO2012063237A3 (en) Buffered ophthalmic compositions and methods of use thereof
MX2010009623A (en) 1-benzyl-3-hydroxymethylindazoiî¹e derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1.
RU2013141845A (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF A CREAM CONTAINING OXYMETAZOLINE FOR THE TREATMENT OF ROSATSEA SYMPTOMS
WO2009090624A3 (en) Chitosan gel for dermatological use, production method therefor and use of same
MX2024000828A (en) ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR THE TREATMENT OF BLEPHARITIS.
EP3653205A3 (en) Oxymethazoline for topical ophthalmic administration and uses thereof
NZ704247A (en) Compositions and treatment for eye diseases and disorders
MX2021010058A (en) Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders.
MX2010009625A (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40.
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
EA201400002A1 (en) METHODS TO TREAT DISEASES OF THE RETAIL
MX2010009624A (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1.
NZ706990A (en) A veterinary method of alleviating noise aversion
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
MY147864A (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
WO2019118779A3 (en) Peptides and other agents for treating pain and increasing pain sensitivity